Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase.

Clinical observations suggest that in chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph+) clone has a growth advantage over normal hematopoiesis. Patients with CML have high levels of neutrophil elastase, which has recently been shown to antagonize the action of granulocyte-colony-stimulating factor (G-CSF) and other growth factors. We therefore compared the effect of elastase on the growth of normal and CML progenitor cells. In 10-day suspension cultures of normal or CML CD34+ cells supplemented with G-CSF, stem cell factor (SCF), and granulocyte macrophage-colony-stimulating factor (GM-CSF), CML cells had diminished sensitivity to the growth inhibitory effect of elastase. When equal numbers of CML and normal CD34+ cells were cocultured for 10 days, there was no change in the relative proportions of normal and leukemic cells (measured by fluorescence in situ hybridization [FISH] or flow cytometry). However, when elastase was added, CML cells predominated at the end of the culture period (78% vs 22% with 1 microg/mL and 80% vs 20% with 5 microg/mL elastase). CML neutrophils substituted effectively for elastase in suppressing the proliferation of normal CD34+ cells, but this effect was abrogated by serine protease inhibitors. These results suggest that elastase overproduction by the leukemic clone can change the growth environment by digesting growth factors, thereby giving advantage to Ph+ hematopoiesis.

[1]  M C Mackey,et al.  Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. , 1998, Blood.

[2]  Jl Lewis,et al.  Cell biology of CML cells , 1999, Leukemia.

[3]  Y. Tsuda,et al.  Determination of leukocyte elastase concentration in plasma and serum by a simple method using a specific synthetic substrate. , 1991, Haemostasis.

[4]  S. Jacobsen,et al.  The growth response of Lin-Thy-1+ hematopoietic progenitors to cytokines is determined by the balance between synergy of multiple stimulators and negative cooperation of multiple inhibitors. , 1994, Experimental hematology.

[5]  H. Kantarjian,et al.  High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. , 1994, Bone marrow transplantation.

[6]  C. Eaves,et al.  Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. , 2001, Blood.

[7]  Z. Darżynkiewicz,et al.  Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells. , 2003, Molecular cancer research : MCR.

[8]  M. Warmuth,et al.  The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. , 2003, Blood.

[9]  B. Zehnbauer,et al.  Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. , 1994, Blood.

[10]  A. Shibata,et al.  Levels of serum granulocyte colony-stimulating factor in patients with chronic myeloid leukemia. , 1993, Leukemia & lymphoma.

[11]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[12]  S. Richards,et al.  Severe cytopenias associated with the sequential use of busulphan and interferon‐alpha in chronic myeloid leukaemia , 1994, British journal of haematology.

[13]  I. Petit,et al.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. , 2002, Experimental hematology.

[14]  S. Heimfeld,et al.  BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. , 1996, Blood.

[15]  S. Scheid,et al.  Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML , 1998, Leukemia.

[16]  F. Benvenuto,et al.  Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation , 1997, Bone Marrow Transplantation.

[17]  M. Jochum,et al.  Plasma levels of human granulocytic elastase α1-proteinase inhibitor complex (E-α1-PI) in leukemia , 1984, Blut Zeitschrift für die gesamte Blutforschung.

[18]  T. Holyoake,et al.  A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia , 2001, Hematological oncology.

[19]  H. Asakura,et al.  Quantitative estimation of elastase-alpha 1-proteinase inhibitor (E-alpha 1 PI) complex in leukemia: marked elevation in cases of acute promyelocytic leukemia. , 1989, Thrombosis research.

[20]  L. Debusscher,et al.  Regulation of bone marrow myeloblast proliferation in chronic myeloid leukemia. , 1976, Cancer research.

[21]  D. Leduc,et al.  Leukocyte Elastase Negatively Regulates Stromal Cell-derived Factor-1 (SDF-1)/CXCR4 Binding and Functions by Amino-terminal Processing of SDF-1 and CXCR4* , 2002, The Journal of Biological Chemistry.

[22]  U. Gullberg,et al.  A secreted proform of neutrophil proteinase 3 regulates the proliferation of granulopoietic progenitor cells. , 1999, Blood.

[23]  E. Buchdunger,et al.  Bcr‐Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors , 1998, British journal of haematology.

[24]  A. Friedman,et al.  GABP cooperates with c-Myb and C/EBP to activate the neutrophil elastase promoter. , 1997, Blood.

[25]  M. Ratajczak,et al.  Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants , 2002, Leukemia.

[26]  J. Melenhorst,et al.  Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. , 2003, Blood.

[27]  T. Holyoake,et al.  A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia , 2001 .

[28]  M Pavelec,et al.  Periodic oscillation of blood leukocytes, platelets, and reticulocytes in a patient with chronic myelocytic leukemia. , 1976 .

[29]  H. Asakura,et al.  Increased levels of plasma thrombomodulin in chronic myelogenous leukemia , 1992, American journal of hematology.

[30]  C. Eaves,et al.  Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. , 1998, Leukemia research.

[31]  I. Olsson,et al.  Suppression of normal granulopoiesis in vitro by a leukemia-associated inhibitor (LAI) of acute and chronic leukemia. , 1980, Blood.

[32]  L. Debusscher,et al.  Cell kinetics in chronic granuclotyci leukaemia (CGL). , 1977, Clinics in haematology.

[33]  H. Asakura,et al.  Quantitative estimation of elastase-α1-proteinase inhibitor (E-α1PI) complex in leukemia: Marked elevation in cases of acute promyelocytic leukemia , 1989 .

[34]  D. Cortez,et al.  The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. , 1996, Oncogene.

[35]  R Ohno,et al.  A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. , 1995, Blood.

[36]  H. Klamová,et al.  Gene Expression Profiling in Chronic Myeloid Leukemia Patients Treated with Hydroxyurea , 2002, Leukemia & lymphoma.

[37]  A. Strife,et al.  New understanding of the pathogenesis of CML: a prototype of early neoplasia , 1997, Leukemia.

[38]  S. Seeber,et al.  Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma. , 1991, Blood.

[39]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[40]  M. Caligiuri,et al.  BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2 , 2002, Nature Genetics.

[41]  C. Eaves,et al.  Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Nilsson,et al.  Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. , 2001, Blood.

[43]  A. Friedman,et al.  C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter , 1996, Molecular and cellular biology.

[44]  E. Lam,et al.  BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival through Modulation of Cyclin D2 and p27Kip1 Expression* , 2001, The Journal of Biological Chemistry.

[45]  J. Lévesque,et al.  Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. , 2003, Experimental hematology.

[46]  D. Cortez,et al.  The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells , 1997, Oncogene.